9.15
+0.66(+7.77%)
Currency In USD
| Previous Close | 8.49 |
| Open | 8.43 |
| Day High | 9.23 |
| Day Low | 8.31 |
| 52-Week High | 55.89 |
| 52-Week Low | 5.2 |
| Volume | 275,691 |
| Average Volume | 521,603 |
| Market Cap | 85.81M |
| PE | -0.97 |
| EPS | -9.42 |
| Moving Average 50 Days | 14.55 |
| Moving Average 200 Days | 19.79 |
| Change | 0.66 |
If you invested $1000 in Korro Bio, Inc. (KRRO) since IPO date, it would be worth $13.36 as of January 08, 2026 at a share price of $9.15. Whereas If you bought $1000 worth of Korro Bio, Inc. (KRRO) shares 5 years ago, it would be worth $5.08 as of January 08, 2026 at a share price of $9.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
8 hours ago
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday,
Korro to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire Inc.
Sep 02, 2025 8:30 PM GMT
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September: Citi's
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
GlobeNewswire Inc.
Jul 21, 2025 12:00 PM GMT
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent di